Get startedLog in
    Picture of Tianda Pharmaceuticals logo

    455 — Tianda Pharmaceuticals Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Tianda Pharmaceuticals, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

    2019
    March 31st
    2020
    March 31st
    2021
    March 31st
    2022
    March 31st
    2023
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    HKAS
    HKAS
    HKAS
    HKAS
    HKAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue527491474510532
    Cost of Revenue
    Gross Profit424361259241256
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses501475501537553
    Operating Profit26.216.3-26.9-27.3-20.7
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes26.215.9-27.4-28-25.7
    Provision for Income Taxes
    Net Income After Taxes168.8-25.9-21.7-25
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income2.663.14-27.1-19.8-24.2
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income2.663.14-27.1-19.8-24.2
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS0.0010.002-0.013-0.012-0.011
    Dividends per Share
    Special Dividends per Share